Johnson & Johnson: Committed to bringing single-dose Covid vaccine to India

Johnson & Johnson: Committed to bringing single-dose Covid vaccine to India

The world is bracing itself for the third wave. Vaccinations are being cited as the biggest defence to safeguard from the virus and its various variants. So far India has approved four vaccines for Emergency use against COVID-19. These include India-made Covaxin and Covishield, Russia's Sputnik V and Moderna. 

On Monday, pharma conglomerate, Johnson & Johnson withdrew its proposal seeking approval of its single-shot COVID-19 vaccine in India. While no reasons were cited for this withdrawal, it later released a media statement saying that it "remains committed" to bringing its single-dose COVID-19 vaccine to the people of India.

"Since the Drugs Controller General of India (DCGI) recently directed that there is no longer a requirement to conduct bridging clinical studies of COVID-19 vaccines in India, Johnson & Johnson withdrew its application to conduct these studies," read the statement that the company has shared via e-mail.

The FDA in the US had given its nod to the single-shot vaccine developed by J&J in February 2021. In April, Johnson & Johnson had sought the approval of Indian regulators to conduct a bridging clinical study for its COVID-19 vaccine. At that time, it was also indicated that this vaccine will become available in the country by July 2021. 

In India, the DGCI had given emergency use authorisation to Moderna's vaccine in June. However, the same is still not being administered in the country. 

As of July 28, only 10 per cent of the population in India has been completely vaccinated. As per the data released by the government, 47 per cent of the people have got at least one of the doses. 

It is expected that the supply of Russia's Sputnik V too will start streaming from this month. 

MumbaiLive would like to send you latest news updates